Phase 1 N=31 Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects
Diabetes · Diabetes Mellitus, Type 2 · Healthy
Primary: Number of Treatment Emergent Adverse Events (TEAEs) — 3; 3; 4; 21 events
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=42 Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia
Alopecia · Alopecia, Androgenetic · Baldness
Primary: Maximum Plasma Level (Cmax) Following a Single Dose of Bimatoprost — 0.552; 1.77; 5.58 Picograms/Milliliter (pg/mL)
Phase 1 N=82 A 2-week Trial Of PF-04991532 In Patients With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Change From Baseline (Day -1) in Mean Daily Glucose at Day 14 — 228.67; 233.20; 219.13; 229.92 milligram/deciliter (mg/dL)
Phase 1 N=46 CP-751,871 In Combination With Docetaxel In Advance Non-hematologic Malignancies
Advanced Non-Hematologic Malignancies
Primary: Maximum Tolerated Dose (MTD) — NA mg/kg
Phase 1 N=12 ORAL T-8 Oral Testosterone for Male Hormonal Contraception
Healthy
Primary: Maximum Testosterone Concentration — 924; 741 ng/dL — p=0.05
Phase 1 N=44 Susceptibility of Motor-Evoked Potentials to Varying Targeted Blood Levels of Dexmedetomidine
Scoliosis
Primary: Motor Evoked Potential Amplitude — 1; 3; 1; 4 participants
Phase 1 N=36 Investigation of Pharmacodynamic Effects of Dabigatran and Ticagrelor and Assessment of Ticagrelor Interaction Potential With Dabigatran
Healthy
Primary: Total Dabigatran (Dabi): Area Under the Curve 0 to Infinity (AUC0-∞) — 281.05; 485.48; 410.46 ng*h/mL
Phase 1 N=32 Bioequivalence of Metformin Under Fed Conditions After Administration of Linagliptin / Metformin Fixed Dose Combination Tablet and Single Tablets
Healthy
Primary: Area Under Curve From 0 to tz Hours (AUC0-tz) of Metformin — 7219.03; 7057.52 ng·h/mL
Phase 1 N=112 Bioequivalence Study of Fixed-dose Combinations and Coadministered Individual Tablets of Saxagliptin/Metformin-Brazil
Type 2 Diabetes Mellitus
Primary: Maximum Observed Concentrations (Cmax) of Metformin, Saxagliptin, and 5-Hydroxy (5-OH) Saxagliptin as a Fixed-dose Combination (FDC) and as Individual Tablets — 713…
Phase 1 N=80 Dosing Study of Cranberry Capsules for the Prevention of Bacteriuria in Nursing Home Residents
Bacteriuria
Primary: E.Coli Bacteriuria Plus Pyuria — 33; 29; 23; 25 urine cultures and urinalyses
Phase 1 N=13 Campath in Chronic GVHD
Chronic Graft-vs.-Host Disease
Primary: The Maximum Tolerated Dose (MTD) of a Four-week Course of Alemtuxumab in Chronic GVHD for Patients With an Incomplete Response to Steroids — 53 mg
Phase 1 N=33 A Pilot Study of Dronabinol for Adult Patients With Primary Gliomas
Brain Neoplasms · Nausea · Vomiting
Primary: Tolerability Rate — 60 percentage of participants
Phase 1 N=48 Pharmacokinetics of Fixed Dose Combination (FDC) Tablets of Linagliptin /Metformin
Healthy
Primary: Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval 0 to 72 Hours (AUC0-72) — 248; 251; 266; 264 nmol*h/L
Phase 1 N=24 Pharmacokinetics of the Brimonidine Tartrate Posterior Segment Delivery System in Patients Undergoing Pars Plana Vitrectomy
Vitrectomy
Primary: Highest Vitreous Humor Level of Brimonidine in the Study Eye — 137.0; 34.9 Nanogram/milliliter (ng/mL)
Phase 1 N=9 Intravenous N-acetylcysteine for the Treatment of Gaucher's Disease and Parkinson's Disease
Parkinson's Disease · Gaucher's Disease
Primary: Brain GSH — 55; 41; 34 percent increase from baseline